# A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

> **NCT04661839** · PHASE1 · COMPLETED · sponsor: **Emergent BioSolutions** · enrollment: 28 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** COVID-HIGIV
- **OTHER:** Placebo (saline)

## Key facts

- **NCT ID:** NCT04661839
- **Lead sponsor:** Emergent BioSolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-24
- **Primary completion:** 2021-07-27
- **Final completion:** 2021-07-27
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04661839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04661839, "A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT04661839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*